



GP 1644  
#

RECEIVED

MAY 04 2000

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David J. Grainger et al.  
Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE  
Docket No.: 295.027US1  
Filed: September 11, 1998  
Examiner: Joseph F. Murphy, Ph.D.  
Serial No.: 09/150,813  
Due Date: N/A  
Group Art Unit: 1644

Assistant Commissioner for Patents  
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- X A return postcard.
- X A Supplemental Information Disclosure Statement (2 pgs.), Forms 1449 (3 pgs.), and copies of 38 cited references.
- X A check in the amount of \$240.00 to cover the fee for consideration of Information Disclosure Statement under 97(c).

Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described above, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 20 day of April, 2000.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Janet E. Embretson  
Atty: Janet E. Embretson  
Reg. No. 39,665

Customer Number **21186**

(GENERAL)

S/N 09/150,813

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David J. Grainger et al.

Examiner: Joseph F. Murphy, Ph.D.

Serial No.: 09/150,813

Group Art Unit: 1644

Filed: September 11, 1998

Docket: 295.027US1

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN  
INFLAMMATORY RESPONSE

P#12

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Forms 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant further requests that a copy of the Forms 1449, initialed by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

The present application is a continuation-in-part application of U.S. patent application Serial No. 08/927,939, filed September 11, 1997, pending.

Applicant has included the fee of \$240.00 under 37 C.F.R. §§ 1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Account No. 19-0743.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial Number: 09/150,813

Filing Date: September 11, 1998

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

Page 2

Dkt: 295.027US1

The Examiner is invited to contact the Applicant's Representatives at the below-listed telephone number if there are any questions regarding this communication.

RECEIVED

MAY 04 2000

TECH CENTER 1600/2500



Respectfully submitted,

DAVID J. GRAINGER ET AL.

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date

April 26, 2000

By

Janet E. Embretson

Janet E. Embretson

Reg. No. 39,665

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231 on April 26, 2000.

Katharine A. Jackson Hubsch

Name

Kath A Jackson Hubsch

Signature



Sheet 1 of 3

Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicant: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1644

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
						Yes	No
	5,684,032	11/04/1997	Elliot et al.				
	5,827,821	09/27/1998	Pierschbacher et al.	514	11		07/16/92
	5,908,829	06/01/1999	Kelly	514	12		03/31/95

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	0807439A2	11/19/1997	European	A61K	38/19		
	0860446	08/26/1998	European	C07K	14/52		
	94/20512	09/15/1994	PCT				
	97/19173	05/29/1997	PCT	C12N	15/19		
	98/24808	06/11/1998	PCT	C07K	7/06		
	99/37617	07/29/1999	PCT				
	99/37619	07/29/1999	PCT				
	99/37651	07/29/1999	PCT				

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)


**Examiner Initial	Document
	Berson, J.F., et al., "Structure-Function Studies of the HIV-1 Coreceptors", <u>Seminars in Immunology</u> , 10, 237-248 (1998).
	Chen, S., et al., "In Vivo Inhibition of CC and CX3C Chemokine-induced Leukocyte Infiltration and Attenuation of Glomerulonephritis in Wistar-Kyoto (WKY) Rats by vMIP-II", <u>J. Exp. Med.</u> , 188, 193-198 (1998).
	Damon, I., et al., "Broad Spectrum Chemokine Antagonistic Activity of a Human Poxvirus Chemokine Homolog", <u>Proc. Natl. Acad. Sci. USA</u> , 95, 6403-6407 (1998).
	Donzella, G.A., et al., "AMD3100, A Small Molecule Inhibition of HIV-1 Entry via the CXCR4 Co-receptor", <u>Nature Medicine</u> , 4, 72-77 (1998).
	Fiocchi, C., "Inflammatory Bowel Disease: Etiology and Pathogenesis", <u>Gastroenterology</u> , 115, 182-205 (1998).
	Hesselgesser, J., et al., "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor", <u>The Journal of Biological Chemistry</u> , 273, 15687-15692 (1998).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449*	Atty. Docket No.: 295.027US1	Serial No. 09/150,813
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: David J. Grainger et al.	
	Filing Date: September 11, 1998	Group: 1644

## OTHER DOCUMENTS

\*\*Examiner  
Initial


(Including Author, Title, Date, Pertinent Pages, Etc.)

Hoffman, G.S., et al., "Wegner Granulomatosis: An Analysis of 158 Patients", <u>Annals of Internal Medicine</u> , 116, 488-498 (1992).
Hogaboam, C.M., et al., "Monocyte Chemoattractant Protein-1 Synthesis by Murine Lung Fibroblasts Modulates CD4+ T Cell Activation", <u>The Journal of Immunology</u> , 160, 4606-4614 (1998).
Howard, O.M., et al., "Inhibition of <i>In Vitro</i> and <i>In Vivo</i> HIV Replication by a Distamycin Analogue That Interferes with Chemokine Receptor Function: A Candidate for Chemotherapeutic and Microbicidal Application", <u>J. Med. Chem.</u> , 41, 2184-2193 (1998).
Hunt, III, S.W., et al., "Chemokine Receptors as HIV Co-Receptors: Targets for Therapeutic Intervention in AIDS", <u>Annual Reports in Medicinal Chemistry</u> , 33, 263-272 (1998).
Karpus, W.J., et al., "Monocyte Chemotactic Protein 1 Regulates Oral Tolerance Induction by Inhibition of T Helper Cell 1-related Cytokines", <u>Journal of Experimental Medicine</u> , 187, 733-741 (1998).
Kim, J.J., et al., "CD8 Positive T Cells Influence Antigen-Specific Immune Responses through the Expression of Chemokines", <u>Journal of Clinical Investigation</u> , 102, 1112-1124 (1998).
Korom, S., et al., "Blockade of Very Late Antigen-4 Integrin Binding to Fibronectin in Allograft Recipients", <u>Transplantation</u> , 65, 854-859 (1998).
Koyoma, S., et al., "Human Lung Fibroblasts Release Chemokinetic Activity for Monocytes Constitutively", <u>Am. J. Physiol.</u> , 275, L223-L230 (1998).
Larkin, et al., "Mycophenolate Mofetil: A New Immunosuppressive for Occular Inflammatory Disease", Abstract 339, <u>IOVS</u> , 39, S215 (1998).
Laycock, K.A., et al., "Reproduction of Antiviral Effect in and <i>In Vivo</i> Model of Human Cytomegalovirus Retinal Infection", <u>Graefe's Arch. Clin. Exp. Ophthalmol.</u> , 236, 527-530 (1998).
Loetscher, et al., "N-terminal Peptides of Stromal Cell-derived Factor-1 with CXC Chemokine Receptor 4 Agonist and Antagonist Activities", <u>The Journal of Biological Chemistry</u> , 273, 22279-22283 (1998).

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPBP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

Applicant: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1644

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

	McFadden, G., et al., "Commentary: New Strategies for Chemokine Induction and Modulation; You Take the High Road and I'll Take the Low Road", <u>Biochemical Pharmacology</u> , 54, 1271-1280 (1997).
	Mekouar, K., et al., "Styrylquinoline Derivatives: A New Class of Potent HIV-1 Integrase Inhibitors That Block HIV-1 Replication in CEM Cells", <u>J. Med. Chem.</u> , 41, 2846-2857 (1998).
	Meltzer, E.O., "Pharmacological Treatment Options for Allergic Rhinitis and Asthma", <u>Clinical and Experimental Allergy</u> , 28, 27-36 (1998).
	Plater-Zyberk, et al., "A Chemokine Receptor Antagonist Reduces the Incidence of Collagen Induced Arthritis", Abstract No. 399, <u>Arthritis &amp; Rheumatism</u> , 41, S99 (1998).
	Roberts, D.J., "Towards the Optimal Antihistamine: Studies with Ebastine", <u>Inflammation Research</u> , 47, S36-S37 (1998).
	Schols, D., et al., "Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4", <u>J. Exp. Med.</u> , 186, 1383-1388 (1997).
	Sekiguchi, K., et al., "Binding of Fibronectin and Its Proteolytic Fragments to Glycosaminoglycans", <u>J. Biol. Chem.</u> , 258, 14359-14365 (1983).
	Struyf, S., et al., "Cutting Edge: Enhanced Anti-HIV-1 Activity and Altered Chemotactic Potency of NH2-Terminally Processed Macrophage-Derived Chemokine (MDC) Imply an Additional MDC Receptor", <u>The Journal of Immunology</u> , 161, 2672-2675 (1998).
	Tomita, H., et al., "Inhibition of NO Synthesis Induces Inflammatory Changes and Monocyte Chemoattractant Protein-1 Expression in Rat Hearts and Vessels", <u>Arterioscler. Thromb. Vasc. Biol.</u> , 18, 1456-1464 (1998).
	Zou, L.P., et al., "Treatment with P2 Protein Peptide 57-81 by Nasal Route is Effective in Lewis Rat Experimental Autoimmune Neuritis", <u>Journal of Neuroimmunology</u> , 85, 137-145 (1998).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.